Misplaced Pages

Revision as of 08:53, 3 November 2011

Rosiglitazone

Clinical data
Trade names	Avandia
AHFS/Drugs.com	Monograph
MedlinePlus	a699023
License data	EU EMA: by INN US FDA: Rosiglitazone
Pregnancy category	AU: B3
Routes of administration	Oral
ATC code	A10BG02 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	99%
Protein binding	99.8%
Metabolism	Hepatic (CYP2C8-mediated)
Elimination half-life	3-4 hours
Excretion	Renal (64%) and fecal (23%)
Identifiers
IUPAC name (RS)-5-ethoxy)benzyl]thiazolidine-2,4-dione
CAS Number	122320-73-4
PubChem CID	77999
IUPHAR/BPS	1056
DrugBank	DB00412
ChemSpider	70383
UNII	05V02F2KDG
ChEBI	CHEBI:50122
CompTox Dashboard (EPA)	DTXSID7037131
ECHA InfoCard	100.108.114
Chemical and physical data
Formula	C18H19N3O3S
Molar mass	357.428 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C1NC(=O)SC1Cc3ccc(OCCN(c2ncccc2)C)cc3
InChI InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23) Key:YASAKCUCGLMORW-UHFFFAOYSA-N
(what is this?)  (verify)

Rosiglitazone is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Annual sales peaked at approximately $2.5bn in 2006, but declined after reports of adverse effects. The drug's patent expires in 2012.

Some reports have found rosiglitazone is associated with an increased risk of heart attacks, but other reports have not found a statistically significant increase. Concern about adverse effects has reduced the use of rosiglitazone despite its sustained effects on glycemic control. The drug is currently the subject of over 13,000 lawsuits against GSK. As of July 2010, GSK has agreed to settlements on more than 11,500 of these suits.

The drug is controversial in the U.S. Some reviewers have concluded that rosiglitazone caused more deaths than pioglitazone (Actos), and have recommended rosiglitazone be taken off the market, but an FDA Food and Drug Administration panel disagreed, and it remains on the market in the U.S., subject to significant restrictions. From November 18, 2011 the federal government will not allow Avandia to be sold without a prescription from certified doctors. Patients will be required to be informed of the risks associated with the use of Avandia, and the drug will be required to be purchased by mail order through specified pharmacies.

In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended from the European market. However, patients currently taking rosiglitazone are advised to discuss alternative options during their next physician appointment.

In the UK, Diabetes UK announced, "People currently taking all forms of the recently suspended drug Avandia (Rosiglitazone) have until 21 October to be reviewed and transferred onto an alternative treatment".

In New Zealand, rosiglitazone (Avandia) is to be withdrawn from the market before April 29, 2011 after concern about its make an elevated risk of cardiovascular events. Patients should discuss alternative treatments with their doctor as soon as possible, but to continue taking the drug in the meantime.

As reported by Medscape/Heartwire 23 September 2010,medscape the EMA has recommended the suspension of the marketing authorizations for all rosiglitazone-containing antidiabetes medications licensed in the EU—Avandia, Avandamet, and Avaglim.

Adverse effects

Heart disease

Some studies conclude rosiglitazone increases fatalities from heart disease, but other studies do not.

A study in 2007 has been widely cited as finding that Avandia may increase the risk of heart attack by as much as 43%.

A meta-analysis in May 2007 reported the use of rosiglitazone was associated with a significantly increased risk of heart attack (odds ratio=1.43, (95% confidence interval, 1.03 to 1.98; P=0.03)), and an even higher risk of death from all cardiovascular diseases (odds ratio=1.64). The U.S. Food and Drug Administration (FDA) issued an alert on May 21, 2007. On July 30, 2007 an Advisory Committee of the Food and Drug Administration concluded the use of rosiglitazone for the treatment of type 2 diabetes was associated with a greater risk of myocardial ischemic events (including heart attacks) than a placebo, but data from several long term, prospective clinical trials showed when rosiglitazone was compared to metformin, or sulfonylurea, there was no difference in the risk of heart attack. These data, coupled with the meta-analysis, prompted the FDA to state the data on the association between rosiglitazone and myocardial ischemia were inconclusive. The meta-analysis was not supported by an interim analysis of the trial designed to evaluate this, and several other reports have failed to conclude the controversy. This weak evidence for adverse effects has dramatically reduced the use of rosiglitazone, despite its important and sustained effects on glycemic control.

The 2009 RECORD study, an open label trial published in the Lancet, found there was no increase in cardiovascular hospitalisation or death with rosiglitazone compared to metformin plus sulfonylurea, but the rate of heart failure causing admission to a hospital or death was significantly increased.

Both TZDs are contraindicated in patients with NYHA Class III and IV heart failure.

In February 2010, David Graham, the FDA's associate director of drug safety, recommended rosiglitazone be taken off the market. Graham argued rosiglitazone caused 500 more heart attacks and 300 more heart failures than its main competitor. At the same time, a report by the Senate Finance Committee accused GlaxoSmithKline of knowing about the drug's risks well before they became public. The report also criticized the FDA for letting clinical trials continue, despite 83,000 heart attacks from 1999 to 2007 that the FDA linked to rosiglitazone. GlaxoSmithKline maintains the drug is safe and that the Senate report did not consider scientific evidence or the company's efforts to make known its concerns to the parties involved. However, the FDA still recommends patients continue taking it unless their doctor tells them otherwise.

In June 2010, Graham et al., published a retrospective study of 227,571 elderly American patients, comparing roziglitazone to pioglitazone, the other thiazolidinedione marketed in the United States. The authors concluded that rosiglitazone was associated with "an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older". The number needed to harm with roziglitazone was sixty.

A meta-analysis of observational studies released in March, 2011 provides more evidence that rosiglitazone is associated with a higher risk of heart failure, myocardial infarction (MI) and death than a similar agent, pioglitazone. The meta-analysis had 16 observational studies involving 810 000 patients taking rosiglitazone or pioglitazone.

Stroke

Avandia has been linked to stroke. In a study led by FDA scientist David J. Graham, MD, MPH., by comparing the patient records of elderly patients using Avandia and alternative drug Actos, found that Avandia increase the risk of stroke by over 27%..

Bone fractures

GlaxoSmithKline reported a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. The information was based on data from the ADOPT trial. The same increase has been found with pioglitazone (Actos), another TZD.

Eye damage

Both rosiglitazone and pioglitazone have been suspected of causing macular edema, which damages the retina of the eye and causes partial blindness. Blindness is also a possible effect of diabetes, which rosiglitazone is intended to treat. One report documented several occurrences and recommended discontinuation at the first sign of vision problems.

Hepatotoxicity

Moderate to severe acute hepatitis has occurred in several adults who had been taking the drug at the recommended dose for two to four weeks. Plasma rosiglitazone concentrations may be significantly increased in patients with pre-existing hepatic impairment.

Pharmacology

Rosiglitazone is a member of the thiazolidinedione class of drugs. Thiazolidinediones act as insulin sensitizers. They reduce glucose, fatty acid, and insulin blood concentrations. They work by binding to the peroxisome proliferator-activated receptors (PPARs). PPARs are receptors on the membrane of the cell nucleus. Thiazolidinediones enter the cell, bind to the nuclear receptors, and affect the expression of DNA. There are several PPARs, including PPARα, PPARβ/δ, and PPARγ. Thiazolidinediones bind to PPARγ.

PPARs are expressed in fat cells, cells of the liver, muscle, heart, and inner wall (endothelium) and smooth muscle of blood vessels. PPARγ is expressed mainly in fat tissue, where it regulates genes involved in fat cell (adipocyte) differentiation, fatty acid uptake and storage, and glucose uptake. It is also found in pancreatic beta cells, vascular endothelium, and macrophages. Rosiglitazone is a selective ligand of PPARγ and has no PPARα-binding action. Other drugs bind to PPARα.

Rosiglitazone also appears to have an anti-inflammatory effect in addition to its effect on insulin resistance. Nuclear factor kappa-B (NF-κB) is a signaling molecule which stimulates the inflammatory pathways. NF-κB inhibitor (IκB) is an inhibitor which downregulates the inflammatory pathways. When patients take rosiglitazone, NF-κB levels fall and IκB levels increase.

Rosiglitazone may also benefit patients with Alzheimer's disease who do not express the ApoE4 allele. This is the subject of a clinical trial currently underway.

Rosiglitazone may also treat mild to moderate ulcerative colitis, due to its anti-inflammatory properties as a PPAR ligand.

A clinical trial has suggested these agents may be of use in treating malaria.

Society and culture

Sales

US sales of the drug were of $2.2 billion in 2006. Sales in 2Q 2007 down 22% compared to 2006. 4Q 2007 sales down to $252 million.

Though sales have gone down since 2007 due to safety concerns, Avandia sales for 2009 totalled $1.2 billion worldwide.

Lawsuits

The Guardian reported lawsuits over the drug could total anywhere from $1 billion to $6 billion. This is based on research by analysts for UBS, who say 13,000 suits have been filed. Included among those suing: Santa Clara County, California, which claims to have spent $2 million on rosiglitazone between 1999 and 2007 at its public hospital and is asking for "triple damages". In May 2010, GlaxoSmithKline (GSK) reached settlement agreements for some of the cases against the company, agreeing to pay $60 million to resolve 700 suits. In July 2010, GSK reached settlement agreements to close another 10,000 of the lawsuits against it, agreeing to pay about $460 million to settle these suits. In a statement, Michael Miller, the attorney representing 1,500 patients in the suit, said about the settlement, "It's a compromise that allows both sides to put this behind them and move on."

Government investigations

The drug has been under investigation in the US and in Europe. In September 2010, the U.S. Food and Drug Administration have decided that rosiglitazone can remain available, but with certain restrictions. Also, the European Medicines Agency (EMA) has decided to stop making all rosiglitazone-containing antidiabetes medication available in Europe. The FDA has decided on revising its prescribing information and medication guides for all rosilitazone containing medicines. The US label for rosiglitazone (Avandia, GlaxoSmithKline) and all rosiglitazone-containing medications (Avandamet and Avandaryl) now includes the additional safety information and restrictions. The revised labels restrict use to patients already taking a rosiglitazone-containing medicine or to new patients who are unable to achieve adequate glycemic control on other diabetes medications and to those, who in consultation with their healthcare provider, have decided not to take Actos (pioglitazone) or other pioglitazone-containing medicines for medical reasons.

United States investigations

The U.S. FDA began investigating the drug in 2007 after reports it likely caused an increased risk in heart attacks, but following a 2007 study, an FDA advisory panel agreed Avandia did not cause a statistically significant increase in heart attacks. The FDA voted to keep the drug on the market; a few months later, however, the agency added a black-box warning about potential heart risks of Avandia. In 2007, a panel of independent researchers reported Avandia could, in fact, increase patients' risk of heart attack, but they recommended it remain on the market. An FDA oversight committee voted in 2007, eight to seven, to accept that advice and keep it on the market.

GlaxoSmithKline is currently being investigated by the FDA and the US Congress regarding Avandia.

Senators Democrat Max Baucus and Republican Charles Grassley filed a report urging GSK to withdraw Avandia in 2008 due to the side effects. The report cited that the drug caused 500 avoidable heart attacks a month and that Glaxo officials sought to intimidate doctors who criticized the drug. It also said GSK continued to sell and promote the drug despite knowing the increased risk of heart attacks and stroke.

The Senate Finance Committee, in a panel investigation, revealed emails from GSK company officials that suggest the company downplayed scientific findings about safety risks dating back to 2000. It was also alleged by the Senate committee that the company initiated a "ghostwriting campaign", whereby GSK sought outside companies to write positive articles about Avandia to submit to medical journals. GSK defended itself by presenting data that its own tests found Avandia to be safe, although an FDA staff report showed the conclusions were flawed. Many studies have found the drug to have serious safety concerns.

On July 14, 2010, after two days of extensive deliberations, the FDA panel investigating Avandia came to a mixed vote. Twelve members of the panel voted to take the drug off the market, 17 recommended to leave it on but with a more revised warning label, and three voted to keep it on the market with the current warning label. The panel has come to some controversy, however; on July 20, 2010, one of the panelists was discovered tohave been a paid speaker for GlaxoSmithKline, arrousing questions of a conflict of interest. This panel member was one of the three who voted to keep Avandia on the market with no additional warning labels. The FDA is expected to vote soon on what to do next in regards to Avandia, though the FDA almost always agrees with its panel votes.

European investigations

According to a probe by the British Medical Journal in September 2010, the United Kingdom's Commission on Human Medicines recommended to the Medicines and Healthcare products Regulatory Agency (MHRA) back in July 2010, to withdraw Avandia sale because its "risks outweigh its benefits". Additionally, the probe revealed that in 2000, members of the European panel in charge of reviewing Avandia prior to its approval had concerns about the long-term risks of the drug. The European Medicines Agency recommended on 23 September 2010 that Avandia be suspended from the European market.

New Zealand

Rosiglitazone was withdrawn from the New Zealand market April 2011 because Medsafe concluded that the suspected cardiovascular risks of the medicine for patients with type 2 diabetes outweigh its benefits. "Patients who are taking Avandia are advised to make an appointment to see their doctor to discuss alternative treatments as soon as possible," the agency's group manager, Stewart Jessamine, says in a media release.

Controversy and response

Following the reports in 2007 that Avandia can significantly increase the risk of heart attacks, the drug has been controversial. A 2010 article in Time uses the Avandia case as evidence of a broken FDA regulatory system that "may prove criminal as well as fatal". It details the disclosure failures, adding "Congressional reports revealed that GSK sat on early evidence of the heart risks of its drug, and that the FDA knew of the dangers months before it informed the public." It reports "the FDA is investigating whether GSK broke the law by failing to fully inform the agency of Avandia's heart risks", according to deputy FDA commissioner Dr. Joshua Sharfstein. GSK threatened academics who reported adverse research results, and received multiple warning letters from the FDA for deceptive marketing and failure to report clinical data.

The maker of the drug, GlaxoSmithKline, has dealt with serious backlash against the company for the drug's controversy. Sales on the drug dropped significantly after the story first broke in 2007, dropping from $2.5 billion in 2006 to less than $408 million in 2009 in the US.

In response to the raise in risk of heart attacks, the Indian government ordered GSK to suspend its research study, called TIDE in 2010. Takeda Pharmaceuticals responded to the controversy by running a large advertising campaign for its rival diabetes drug Actos, first in 2007 and again in 2010. The FDA also halted the TIDE study in the United States.

Three doctors' groups, the Endocrine Society, the American Diabetes Association and the American Association of Clinical Endocrinologists, urged patients to continue to take the drug as it would be much worse to stop all treatment, despite any associated risk, but that patients could consult their doctors and begin a switch to a different drug if they or their doctor find concern. The American Heart Association said in a statement in June 2010: " ...the reports deserves serious consideration, and patients with diabetes who are 65 years of age or older and being treated with rosiglitazone should discuss the findings with their prescribing physician....". "For patients with diabetes, the most serious consequences are heart disease and stroke, and the risk of suffering from them is significantly increased when diabetes is present. As in most situations, patients should not change or stop medications without consulting their healthcare provider."

Some doctors have been reported to have begun to stop prescribing Avandia.

PCRM lawsuit

On July 19, 2010 the nonprofit group Physicians Committee for Responsible Medicine (PCRM) announced they were suing the FDA for failing to notify patients of dietary substitutes for diabetes drugs. The lawsuit, filed in the U.S. District Court for the District of Columbia, is currently underway.

References

1. Details for patent 5,002,953
2. ^ Ajjan RA, Grant PJ (2008). "The cardiovascular safety of rosiglitazone". Expert Opin Drug Saf. 7 (4): 367–76. doi:10.1517/14740338.7.4.367. PMID 18613801.
3. ^ http://www.businessweek.com/news/2010-07-10/ex-regulator-said-to-testify-glaxosmithkline-withheld-study.html
4. Controversial Diabetes Drug Harms Heart, U.S. Concludes By GARDINER HARRIS, New York Times, February 19, 2010
5. "Most Popular E-mail Newsletter". USA Today. 2011-05-24.
6. ^ http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=false
7. http://diabetes.org.uk/About_us/News_Landing_Page/Final-date-to-switch-onto-Avandia-alternative/
8. http://www.stuff.co.nz/the-press/news/christchurch/4669573/Diabetes-drug-withdrawn
9. ^ http://www.bbc.co.uk/news/health-11397645 Call to 'suspend' diabetes drug
10. LA Times Avandia: When does a drug's harm outweigh its benefit? by David Lazarus. 1 July 2010. Access date: July 24, 2010
11. http://news.bostonherald.com/news/opinion/editorials/view.bg?articleid=1268462&srvc=home&position=emailed
12. Nissen SE, Wolski K (2007). "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes". N Engl J Med. 356 (24): 2457–71. doi:10.1056/NEJMoa072761. PMID 17517853. {{cite journal}}: Unknown parameter |laydate= ignored (help); Unknown parameter |laysource= ignored (help); Unknown parameter |laysummary= ignored (help)
13. U.S. Food and Drug Administration (May 21, 2007). "FDA Issues Safety Alert on Avandia".
14. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. The Lancet. In Press, Corrected Proof. Available at: http://www.sciencedirect.com/science/article/B6T1B-4WGD87Y-1/2/0efabb7eba7ca1f4f7c556bd636e19ab.
15. "Diabetes Drug Avandia Targeted By Reviewers on Safety". ABC News. 2010-02-23.
16. ^ Ranii, David (2010-02-23). "Avandia fallout could hit Triangle". News & Observer. Retrieved 2010-03-05.
17. Graham, D.J. et al.: Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone. JAMA. 2010;304(4):(doi:10.1001/jama.2010.920) Full text
18. Hughes, Sue (27 March 2011). "More damning data on rosiglitazone". theheart.org. Retrieved 6 April 2011.
19. Freeman, David W (2010-06-29). "Diabetes Drug and Risk: Avandia Linked to Stroke, Heart Trouble, Deaths". CBS News.
20. Elizabeth Agnvall (2010-06-28). "Drug Safety: Diabetes Drug Found to Increase Risk of Stroke, Heart Attack and Death. Researchers question why Avandia has not been removed from the market". AARP Bulletin. Retrieved 2011-11-03.
21. Daniel J. DeNoon (2010-06-28). "New Study: Avandia Riskier Than Actos: More Deaths, Heart Failure, Strokes in Elderly Patients Taking Diabetes Drug Avandia vs. Actos". WebMD Health News. {{cite news}}: Unknown parameter |review= ignored (help)
22. Cobitz, Alexander R (February 2007). Template:PDFlink. GlaxoSmithKline. Retrieved on 10 April 2007.
23. Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N, Kravitz B, Lachin J, O'Neill M, Zinman B, Viberti G (2006). "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy". N Engl J Med. 355 (23): 2427–43. doi:10.1056/NEJMoa066224. PMID 17145742.{{cite journal}}: CS1 maint: multiple names: authors list (link)
24. CMAJ
25. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1399-1400.
26. Thiazolidinediones, Hannele Yki-Järvinen, New Engl J Med 351:1106-1118 (September 9, 2004)
27. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P (2004). "Evidence for a potent antiinflammatory effect of rosiglitazone". J Clin Endocrinol Metab. 89 (6): 2728–35. doi:10.1210/jc.2003-032103. PMID 15181049.{{cite journal}}: CS1 maint: multiple names: authors list (link)
28. Risner ME; et al. (2006). "Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease". The Pharmacogenomics Journal. 6 (4): 246–254. doi:10.1038/sj.tpj.6500369. PMID 16446752. {{cite journal}}: Explicit use of et al. in: |author= (help)
29. http://www.alzforum.org/drg/drc/detail.asp?id=116
30. Lewis JD, Lichtenstein GR, Deren JJ; et al. (2008). "Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo Controlled Trials". Gastroenterology. 134 (5): 688–695. doi:10.1053/j.gastro.2008.03.030. PMID 18471502. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
31. Boggild AK, Krudsood S, Patel SN, Serghides L, Tangpukdee N, Katz K, Wilairatana P, Liles WC, Looareesuwan S, Kain KC (2009). "Use of Peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: A randomized, double-blind, placebo-controlled trial". Clin. Infect. Dis.{{cite journal}}: CS1 maint: multiple names: authors list (link)
32. http://www.mmm-online.com/FDA-toughens-Avandia-warnings/article/96354/
33. Rubin, Rita (2007-07-26). "FDA panels to weigh Avandia heart risks". USA Today. Retrieved 2010-05-22.
34. http://www.bloomberg.com/apps/news?pid=20601087&sid=aHobgoX8jyfg&refer=home
35. Ranii, David (2010-03-05). "Avandia could cost GSK billions". News & Observer. Retrieved 2010-03-05.
36. Ranii, David (2010-03-01). "California county sues Glaxo over diabetes drug". News & Observer. Retrieved 2010-03-05.
37. http://www.bloomberg.com/news/2010-05-10/glaxo-said-to-pay-about-60-million-in-first-settlement-of-avandia-drug.html
38. http://noir.bloomberg.com/apps/news?pid=newsarchive&sid=aP.inHBfGVcU
39. Dawber, Alistair (2010-07-14). "GSK 'settles Avandia claims' on first day of safety hearing". The Independent. London.
40. http://www.fiercepharma.com/story/gsk-settles-bulk-avandia-suits-460m/2010-07-14?utm_medium=nl&utm_source=internal
41. Wood, Shelley. "FDA restricts rosiglitazone; EMA pulls the plug". http://www.theheart.org. Retrieved 1 April 2011. {{cite web}}: External link in |publisher= (help)
42. O'Riordan, Michael. "New rosiglitazone label includes restrictions on use". http://www.theheart.org. Retrieved 1 April 2011. {{cite web}}: External link in |publisher= (help)
43. "GSK revises US Avandia label to include new restrictions on use". http://www.gsk.com. Retrieved 1 April 2011. {{cite web}}: External link in |publisher= (help)
44. http://www.aarp.org/health/drugs-supplements/info-06-2010/diabetes_drug_found_to_increase_risk_of_stroke_heart_failure_and_death.2.html
45. Lazarus, David (2010-07-01). "Avandia: When does a drug's harm outweigh its benefit?". The Los Angeles Times.
46. http://www.portfolio.com/views/blogs/heavy-doses/2010/07/14/medical-experts-vote-on-whether-to-pull-avandia-from-market#ixzz0tgGHXXRG
47. http://www.portfolio.com/views/blogs/heavy-doses/2010/07/09/avandia-safety-questioned-again-before-a-government-panel-review
48. http://www.portfolio.com/views/blogs/heavy-doses/2010/06/28/avandia-heart-risks-found-in-two-studies
49. http://www.fiercepharma.com/story/breaking-news-12-panel-members-recommend-avandia-withdrawal/2010-07-14
50. http://www.fiercepharma.com/story/what-does-avandia-vote-mean/2010-07-14?utm_medium=nl&utm_source=internal
51. http://www.pharmalot.com/2010/07/an-undisclosed-conflict-on-the-fda-avandia-panel/
52. Mundy, Alicia (2010-07-20). "Panelist Who Backed Avandia Gets Fees From Glaxo". The Wall Street Journal.
53. Gallagher, James (2010-07-20). "Report: Avandia panelist paid by GSK".
54. Douglas, Jason (2010-09-06). "U.K. Medical Journal Questions Avandia License". The Wall Street Journal.
55. http://www.fiercepharma.com/story/u-k-watchdogs-vote-avandia-withdrawal/2010-09-07?utm_medium=nl&utm_source=internal
56. "Diabetes drug to be withdrawn over heart risk fears". New Zealand Herald. Feb 17, 2011.
57. http://www.nzdoctor.co.nz/news/2011/february-2011/17/avandia-to-be-withdrawn-in-april.aspx (subscription required)
58. After Avandia: Does the FDA Have a Drug Problem? Time, Thursday, Aug. 12, 2010, http://www.time.com/time/health/article/0,8599,2010028,00.html
59. http://health.usnews.com/health-news/managing-your-healthcare/diabetes/articles/2010/07/09/will-avandia-be-yanked-off-the-market.html
60. http://www.mmm-online.com/exclusive-takeda-launches-actos-dtc-campaign-today/article/174652/
61. http://wwj.cbslocal.com/2010/07/14/avandia-drug-trials-shut-down-in-india/
62. http://www.pharmalot.com/2010/07/india-suspends-avandia-clinical-trials-over-risks/
63. http://www.fiercepharma.com/story/india-suspends-tide-takeda-touts-actos/2010-07-16?utm_medium=nl&utm_source=internal
64. ^ http://www.foodconsumer.org/newsite/Non-food/Drug/fda_orders_glaxo_to_stop_an_avandia_trial_2307100700.html
65. "Don't dump Avandia, diabetes groups urge patients". Reuters. 2010-07-15.
66. Maugh II, Thomas H. (2010-07-15). "Patients taking Avandia should keep on doing so, doctor groups say". The Los Angeles Times.
67. Katz, Neil (2010-07-16). "Avandia News: What You Need to Know". CBS News.
68. "Booster Shots". The Los Angeles Times. 2010-06-29.
69. http://www.redorbit.com/news/health/1892007/american_heart_association_comment_advisory_committee_recommends_that_us_food/index.html?source=r_health
70. Rubin, Rita (2010-07-19). "Doctors say it's already over for diabetes drug Avandia". USA Today.
71. http://www.californiahealthline.org/articles/2010/7/19/physicians-weighing-benefits-risks-of-prescribing-avandia.aspx
72. http://www.medscape.com/viewarticle/725422
73. http://www.justicenewsflash.com/2010/07/23/fda-sued-for-failure-to-alert-diabetics_201007235075.html
74. http://www.pcrm.org/news/avandia_pcrm_lawsuit_1007.html

External links

• Official website
• MedlinePlus article
• Medscape
• Clinical trial number NCT00265148 for "Brain Imaging Study of Rosiglitazone Efficacy and Safety in Alzheimer's Disease" at ClinicalTrials.gov
• U.S. National Library of Medicine: Drug Information Portal - Rosiglitazone

• Thiazolidinediones
• Pyridines
• GlaxoSmithKline
• Phenol ethers